核心结合因子白血病的临床突变图谱
该研究对292例成人核心结合因子(CBF)白血病患者进行129个基因的靶向测序,描绘其非沉默突变谱。CBFB/MYH11与RUNX1/RUNX1T1两个亚组间存在根本性突变差异,KIT、SMC1A、DHX15等基因突变具预后意义,并发现NFE2、MN1、HERC1、ZFHX4等新发反复突变。年龄>60岁、非原发AML和Y染色体缺失也是重要生存预测因素。
要点
- ASXL2、JAK2、JAK3、RAD21、TET2、ZBTB7A突变与RUNX1/RUNX1T1亚组强相关
- KIT、SMC1A、DHX15突变具预后意义,NFE2(3%)、MN1(4%)、HERC1(3%)、ZFHX4(5%)为新发反复突变
- 年龄>60岁、非原发AML和Y染色体缺失是重要生存预测因素
核心结论
- CBF白血病的突变谱在CBFB/MYH11与RUNX1/RUNX1T1两个亚组间存在根本差异,多个基因突变具预后意义,有助于细化治疗分层和开发靶向治疗。
研究设计与样本
- 对292例成人CBF白血病患者进行129个基因的靶向测序,鉴定非沉默突变。
主要发现
- ASXL2、JAK2、JAK3、RAD21、TET2、ZBTB7A与RUNX1/RUNX1T1亚组强相关。
- KIT、SMC1A、DHX15突变具预后意义。
- 发现NFE2(3%)、MN1(4%)、HERC1(3%)、ZFHX4(5%)新发反复突变。
- 年龄>60岁、非原发AML和Y染色体缺失是重要生存预测因素。
关键数值与推荐
- CBFB/MYH11和RUNX1/RUNX1T1融合见于10-15%的成人原发AML。
- NFE2突变频率3%,MN1为4%,HERC1为3%,ZFHX4为5%。
临床怎么用
- 对CBF白血病患者可结合突变谱(如KIT、SMC1A、DHX15及新发突变)与年龄、AML原发性和Y染色体状态细化预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The fusion genes CBFB/MYH11 and RUNX1/RUNX1T1 block differentiation through disruption of the core binding factor (CBF) complex and are found in 10-15% of adult de novo acute myeloid leukemia (AML) cases. This AML subtype is associated with a favorable prognosis; however, nearly half of CBF-rearranged patients cannot be cured with chemotherapy. This divergent outcome might be due to additional mutations, whose spectrum and prognostic relevance remains hardly defined. Here, we identify nonsilent mutations, which may collaborate with CBF-rearrangements during leukemogenesis by targeted sequencing of 129 genes in 292 adult CBF leukemia patients, and thus provide a comprehensive overview of the mutational spectrum ('mutatome') in CBF leukemia. Thereby, we detected fundamental differences between CBFB/MYH11- and RUNX1/RUNX1T1-rearranged patients with ASXL2, JAK2, JAK3, RAD21, TET2, and ZBTB7A being strongly correlated with the latter subgroup. We found prognostic relevance of mutations in genes previously known to be AML-associated such as KIT, SMC1A, and DHX15 and identified novel, recurrent mutations in NFE2 (3%), MN1 (4%), HERC1 (3%), and ZFHX4 (5%). Furthermore, age >60 years, nonprimary AML and loss of the Y-chromosomes are important predictors of survival. These findings are important for refinement of treatment stratification and development of targeted therapy approaches in CBF leukemia.
引用
- Opatz S, Bamopoulos SA, Metzeler KH, et al. The clinical mutatome of core binding factor leukemia. Leukemia. 2020. PMID: 31896782. doi:10.1038/s41375-019-0697-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。